Avadel Pharma

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its products include Bloxiverz, Vazculep, Nouress, and Akovaz. It focuses on the approval of FT218, a formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was founded in 1990 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Avadel Pharma reports robust Q3 revenue, eyes market expansion

Avadel Pharma's Q3 performance showed solid revenue and positive EBITDA, with strong patient demand for LUMRYZ.
Despite legal challenges and competition, opportunities exist in market expansion and new patient segments.
The company's focus on persistency, market growth, and product efficacy positions it for future success.
Maintaining strong payer coverage and cash flow positivity are key priorities for upcoming quarters.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.

New York, New York--(Newsfile Corp. - June 15, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Avadel Pharmaceuticals plc (""or the "Company") (NASDAQ: AVDL). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Avadel and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avadel Pharmaceuticals plc - AVDL

DUBLIN, Ireland, June 03, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it entered into an exclusive collaboration with the American Academy of Sleep Medicine (AASM) Foundation, to support its 2022 Young Investigators Research Forum (YIRF), providing scholarships and research training to early career sleep medicine researchers.

Avadel Pharmaceuticals and the American Academy of Sleep Medicine Foundation Announce an Exclusive Collaboration on the 2022 Young Investigators Research Forum

Tellurian

Exela Technologies

What you need to know about trading penny stocks right now The post How to Make Money With Penny Stocks in June, 3 Tips  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Make Money With Penny Stocks in June, 3 Tips

Allarity Therapeutics

BlackSky Technology

Inovio Pharmaceuticals

BitNile Holdings

Are these penny stocks to buy or avoid right now? The post Top Penny Stocks Today: What's Moving AVDL, BKSY, NILE, INO, & ALLR appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks Today: What's Moving AVDL, BKSY, NILE, INO, & ALLR

Shares of Avadel Pharmaceuticals PLC AVDL, -8.15% tumbled 21.6% in premarket trading on Thursday after the company said in a securities filing that the Food and Drug Administration requested additional information for its experimental narcolepsy drug. Avadel said it now expects to get a FDA decision on the drug, FT218, by June of next year.

Avadel's stock falls 21% after disclosing new FDA request for experimental narcolepsy drug

DUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Wednesday, May 25 at 8:30 a.m. E.T.

Avadel Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

Avadel Pharmaceuticals PLC (NASDAQ: AVDL) reported 1Q results and provided updated color on the U.S. marketing application for FT218. FT218 is once nightly sodium oxybate for narcolepsy, which would compete with Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) twice-nightly franchise.

What Does HC Wainwright Have To Say On Avadel's Narcolepsy Candidate's Potential Approval

Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q1 2022 Earnings Conference Call May 9, 2022 8:30 AM ET Company Participants Brandi Robinson - Senior Vice President of Corporate Affairs Douglas Williamson - Chief Medical Officer Gregory Divis - Chief Executive Officer Jennifer Gudeman - Vice President of Medical & Clinical Affairs Richard Kim - Chief Commercial Officer Tom McHugh - Senior Vice President & Chief Financial Officer Conference Call Participants Francois Brisebois - Oppenheimer Marc Goodman - SVB Securities Oren Livnat - H.C. Wainwright Matt Kaplan - Laddenburg Robin Garner - Craig Hallum Adam Evertts - LifeSci Capital Operator Ladies and gentlemen, thank you for standing by and welcome to the Avadel Pharmaceuticals' First Quarter 2022 Earnings Call.

Avadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q1 2022 Results - Earnings Call Transcript

DUBLIN, Ireland, May 09, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update, and announced its financial results for the first quarter ended March 31, 2022.

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results

DUBLIN, Ireland, May 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 9, 2022, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2022.

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter Financial Results on May 9

The stock is rebounding from Monday's sell-off after a public statement from the company.

Why Avadel Pharmaceuticals Stock Is Skyrocketing Today

Agile Therapeutics

Venator Materials

Here's what you need to know about trading penny stocks on April 26th The post Hot Penny Stocks to Buy Today? 3 For Your Watchlist  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Buy Today? 3 For Your Watchlist

DUBLIN, Ireland, April 26, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a statement in response to the trading volatility and subsequent brief trading halt of its shares that occurred yesterday.

Avadel Pharmaceuticals Provides Comment on Recent Trading Activity

DUBLIN, Ireland, April 25, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the presentation of interim data from the ongoing RESTORE open-label extension/switch study of FT218 at the 2022 American Academy of Neurology Annual (AAN) Meeting being held virtually from April 24-26, 2022. FT218 is the Company's lead drug candidate, an investigational formulation of sodium oxybate designed to be taken once at bedtime for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. The presentation highlights results from a questionnaire assessing patient preference for the once-nightly versus twice-nightly dosing regimen and another questionnaire assessing experiences with the second nightly dose in patients who switched from twice-nightly oxybates to FT218.

Avadel Pharmaceuticals Announces Interim Data from the Open-Label RESTORE Study at the 2022 American Academy of Neurology Annual Meeting

We are initiating AVDL at a speculative buy rating, with a target price of USD 14.

Avadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To Sleepiness

Avadel Pharmaceuticals plc's (AVDL) CEO Gregory Divis on Q4 2021 Results - Earnings Call Transcript

DUBLIN, Ireland, March 17, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the fourth quarter and full year ended December 31, 2021.

Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

DUBLIN, Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Brandi Robinson to the newly created position of Senior Vice President, Corporate Affairs.

Avadel Pharmaceuticals Announces Appointment of Brandi Robinson as Senior Vice President, Corporate Affairs

DUBLIN, Ireland, March 11, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced new data will be presented in eight posters at the World Sleep 2022 congress in Rome. The presentations will feature results from a discrete choice experiment (DCE) designed to characterize and quantify drivers of preferences for attributes associated with oxybate treatments for narcolepsy, with a background survey providing patient and clinician perspectives on narcolepsy disease burden, treatment approaches and satisfaction with current narcolepsy treatment options. New post-hoc data from the completed pivotal Phase 3 REST-ON clinical trial of FT218 and interim data from the ongoing RESTORE open-label extension/switch study of FT218 will also be presented.

Avadel Announces New Positive Data for Once-at-Bedtime FT218 for Narcolepsy and Once-Nightly Dosing Preference Among Patients and Clinicians at World Sleep 2022

DUBLIN, Ireland, March 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in participate in a virtual fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on Thursday, March 17 at 10:40 a.m. ET.

Avadel Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference

DUBLIN, Ireland, March 01, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today it will present eight posters at World Sleep 2022, taking place March 11-16 in Rome, Italy. The presentations will feature new data from the completed pivotal Phase 3 REST-ON clinical trial of FT218 and the ongoing RESTORE open-label extension/switch study of FT218. Results from discrete choice experiments designed to understand patient and healthcare provider preferences associated with oxybate treatments for narcolepsy and perspectives on narcolepsy disease burden, treatment approaches and satisfaction with current narcolepsy treatment options will also be presented. FT218, also known as ON-SXB, is the Company's lead drug candidate, an investigational formulation of sodium oxybate designed to be taken once at bedtime for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. FT218 is currently under review at the U.S. Food and Drug Administration.

Avadel to Present New Clinical Data at World Sleep 2022

DUBLIN, Ireland, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Douglas Williamson, MBChB, as Chief Medical Officer.

Avadel Pharmaceuticals Appoints Dr. Douglas Williamson as Chief Medical Officer

DUBLIN, Ireland, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17 at 1:40 p.m. ET.

Avadel Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Investors need to pay close attention to Avadel (AVDL) stock based on the movements in the options market lately.

Do Options Traders Know Something About Avadel (AVDL) Stock We Don't?

Avadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q3 2021 Results - Earnings Call Transcript

News for Avadel Pharma Stock (AVDL)